To compare the effect of transdermal and oral estrogen therapy, the latter with or without the addition of gestodene, on plasma concentrations of markers of endothelial function and on ultrasonographic parameters of vascular function in healthy postmenopausal women.In a 15-month, randomized, double-blind, placebo-controlled study, 152 healthy hysterectomized postmenopausal women received daily doses of placebo (n = 49), 50 microg of transdermal 17ss-estradiol (tE2, n = 33), 1 mg of oral E2 (oE2, n = 37), or 1 mg of oral estradiol combined with 25 microg of gestodene (oE2+ G, n = 33) for 13 cycles of 28 days, followed by four washout cycles with placebo in each group. At baseline and in cycles 4, 13, and 17, we measured plasma levels of endothelial markers and ultrasonographic markers of vascular function (pulsatility index [PI] and, at baseline and cycle 13, arterial stiffness).Compared with placebo, we found reductions in soluble vascular cell adhesion molecule (oE2, P inconclusive.
|Journal||Menopause-The Journal of the North American Menopause Society|
|Publication status||Published - 1 Jan 2005|
Hemelaar, M., van der Mooren, M. J., van Baal, W. M., Schalkwijk, C. G., Kenemans, P., & Stehouwer, C. D. A. (2005). Effects of transdermal and oral postmenopausal hormone therapy on vascular function a randomized placebo-controlled study in healthy postmenopausal women. Menopause-The Journal of the North American Menopause Society, 12, 526-535. https://doi.org/10.1097/01.GME.0000153888.94399.AF